BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2845169)

  • 21. [The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes].
    Nozawa S; Yajima M; Udagawa Y; Kiguchi K; Iizuka R; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1823-9. PubMed ID: 2687409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A study of amplifications of myc gene (c-myc and N-myc) in human ovarian cancer].
    Kataoka A; Yakushiji M; Kojiro M
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Mar; 42(3):259-63. PubMed ID: 2332674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-myc Gene amplification in primary stomach cancer.
    Koda T; Matsushima S; Sasaki A; Danjo Y; Kakinuma M
    Jpn J Cancer Res; 1985 Jul; 76(7):551-4. PubMed ID: 2993214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Ca 125 as tumor marker in ovarian carcinoma.
    Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
    Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary.
    Filmus JE; Buick RN
    Cancer Res; 1985 Sep; 45(9):4468-72. PubMed ID: 4028028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers in the ovary.
    Berchuck A
    J Cell Biochem Suppl; 1995; 23():223-6. PubMed ID: 8747400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [CA-125 values in fluid and serum in females with cystic ovarian tumors].
    Sautter T; Mickan H
    Gynakol Rundsch; 1990; 30 Suppl 1():208-9. PubMed ID: 2079272
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical applications of CA 125 carcinoma of the ovary].
    Tomioka E; Fujita MM; Izaki M; Lin WF; Moriyama AJ; Bastos Ada C
    Rev Paul Med; 1991; 109(3):123-30. PubMed ID: 1947608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
    Shi W; Zhang YJ; Jiang CY
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of tumour marker measurements upon management of patients with carcinoma of the ovary.
    Rustin GJ
    Dis Markers; 1991; 9(3-4):153-8. PubMed ID: 1813207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Amplification of proto-oncogenes C-myc, C-N-ras, C-Ki-ras, C-erbB2 in ovarian carcinoma].
    Bian M; Fan Q; Huang S
    Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):406-9. PubMed ID: 7587576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
    Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
    Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors].
    Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1985 Feb; 33(2):173-7. PubMed ID: 3858562
    [No Abstract]   [Full Text] [Related]  

  • 39. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.
    Katsaros D; Theillet C; Zola P; Louason G; Sanfilippo B; Isaia E; Arisio R; Giardina G; Sismondi P
    Anticancer Res; 1995; 15(4):1501-10. PubMed ID: 7654038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined use of tumor markers and MRI tomography in differential diagnosis of ovarian neoplasms].
    Pavlov SB; Akulina EA; Pavlova GB
    Klin Med (Mosk); 1999; 77(4):49-51. PubMed ID: 10356919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.